vs
Apellis Pharmaceuticals, Inc.（APLS）与Mayville Engineering Company, Inc.（MEC）财务数据对比。点击上方公司名可切换其他公司
Apellis Pharmaceuticals, Inc.的季度营收约是Mayville Engineering Company, Inc.的1.5倍（$199.9M vs $134.3M），Mayville Engineering Company, Inc.净利率更高（-3.2% vs -29.5%，领先26.2%），Mayville Engineering Company, Inc.同比增速更快（10.7% vs -5.9%），Mayville Engineering Company, Inc.自由现金流更多（$10.2M vs $-14.3M），过去两年Apellis Pharmaceuticals, Inc.的营收复合增速更高（7.7% vs -8.8%）
Apellis Pharmaceuticals是一家临床阶段生物制药企业，专注于开发调节补体系统的靶向疗法，适应症覆盖年龄相关性黄斑变性继发地图样萎缩等眼科疾病、罕见血液病及自身免疫性疾病，核心市场为美国及欧盟地区。
Mayville Engineering Company（MEC）是总部位于美国的领先金属零部件、装配组件及定制工程解决方案供应商，主要服务农业、建筑、商用运输、国防、动力运动等领域的原始设备制造商客户，提供从原型开发到大规模量产的全流程服务。
APLS vs MEC — 直观对比
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $199.9M | $134.3M |
| 净利润 | $-59.0M | $-4.4M |
| 毛利率 | — | 6.8% |
| 营业利润率 | -25.6% | -4.1% |
| 净利率 | -29.5% | -3.2% |
| 营收同比 | -5.9% | 10.7% |
| 净利润同比 | -62.2% | -127.3% |
| 每股收益（稀释后） | $-0.40 | $-0.22 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
| Q4 25 | $199.9M | $134.3M | ||
| Q3 25 | $458.6M | $144.3M | ||
| Q2 25 | $178.5M | $132.3M | ||
| Q1 25 | $166.8M | $135.6M | ||
| Q4 24 | $212.5M | $121.3M | ||
| Q3 24 | $196.8M | $135.4M | ||
| Q2 24 | $199.7M | $163.6M | ||
| Q1 24 | $172.3M | $161.3M |
| Q4 25 | $-59.0M | $-4.4M | ||
| Q3 25 | $215.7M | $-2.7M | ||
| Q2 25 | $-42.2M | $-1.1M | ||
| Q1 25 | $-92.2M | $20.0K | ||
| Q4 24 | $-36.4M | $16.0M | ||
| Q3 24 | $-57.4M | $3.0M | ||
| Q2 24 | $-37.7M | $3.8M | ||
| Q1 24 | $-66.4M | $3.2M |
| Q4 25 | — | 6.8% | ||
| Q3 25 | — | 11.0% | ||
| Q2 25 | — | 10.3% | ||
| Q1 25 | — | 11.3% | ||
| Q4 24 | — | 8.9% | ||
| Q3 24 | — | 12.6% | ||
| Q2 24 | — | 13.6% | ||
| Q1 24 | — | 13.0% |
| Q4 25 | -25.6% | -4.1% | ||
| Q3 25 | 48.7% | 0.0% | ||
| Q2 25 | -18.6% | 0.1% | ||
| Q1 25 | -50.0% | 1.2% | ||
| Q4 24 | -12.3% | 19.0% | ||
| Q3 24 | -24.0% | 4.2% | ||
| Q2 24 | -14.7% | 5.0% | ||
| Q1 24 | -36.0% | 4.7% |
| Q4 25 | -29.5% | -3.2% | ||
| Q3 25 | 47.0% | -1.9% | ||
| Q2 25 | -23.6% | -0.8% | ||
| Q1 25 | -55.3% | 0.0% | ||
| Q4 24 | -17.1% | 13.2% | ||
| Q3 24 | -29.2% | 2.2% | ||
| Q2 24 | -18.9% | 2.3% | ||
| Q1 24 | -38.5% | 2.0% |
| Q4 25 | $-0.40 | $-0.22 | ||
| Q3 25 | $1.67 | $-0.13 | ||
| Q2 25 | $-0.33 | $-0.05 | ||
| Q1 25 | $-0.74 | $0.00 | ||
| Q4 24 | $-0.30 | $0.76 | ||
| Q3 24 | $-0.46 | $0.14 | ||
| Q2 24 | $-0.30 | $0.18 | ||
| Q1 24 | $-0.54 | $0.16 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $466.2M | $1.5M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $370.1M | $240.7M |
| 总资产 | $1.1B | $563.6M |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
| Q4 25 | $466.2M | $1.5M | ||
| Q3 25 | $479.2M | $1.2M | ||
| Q2 25 | $370.0M | $206.0K | ||
| Q1 25 | $358.4M | $183.0K | ||
| Q4 24 | $411.3M | $206.0K | ||
| Q3 24 | $396.9M | $178.0K | ||
| Q2 24 | $360.1M | $314.0K | ||
| Q1 24 | $325.9M | $314.0K |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | $93.1M | — |
| Q4 25 | $370.1M | $240.7M | ||
| Q3 25 | $401.2M | $244.8M | ||
| Q2 25 | $156.3M | $246.8M | ||
| Q1 25 | $164.2M | $250.0M | ||
| Q4 24 | $228.5M | $251.8M | ||
| Q3 24 | $237.1M | $238.4M | ||
| Q2 24 | $264.3M | $238.1M | ||
| Q1 24 | $266.7M | $234.0M |
| Q4 25 | $1.1B | $563.6M | ||
| Q3 25 | $1.1B | $585.6M | ||
| Q2 25 | $821.4M | $433.7M | ||
| Q1 25 | $807.3M | $447.7M | ||
| Q4 24 | $885.1M | $445.6M | ||
| Q3 24 | $901.9M | $466.0M | ||
| Q2 24 | $904.5M | $488.2M | ||
| Q1 24 | $831.9M | $499.9M |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | 0.35× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-14.2M | $13.4M |
| 自由现金流经营现金流 - 资本支出 | $-14.3M | $10.2M |
| 自由现金流率自由现金流/营收 | -7.1% | 7.6% |
| 资本支出强度资本支出/营收 | 0.1% | 2.4% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $45.0M | $26.9M |
8季度趋势，按日历期对齐
| Q4 25 | $-14.2M | $13.4M | ||
| Q3 25 | $108.5M | $1.9M | ||
| Q2 25 | $4.4M | $15.0M | ||
| Q1 25 | $-53.4M | $8.3M | ||
| Q4 24 | $19.4M | $38.0M | ||
| Q3 24 | $34.1M | $17.9M | ||
| Q2 24 | $-8.3M | $23.3M | ||
| Q1 24 | $-133.0M | $10.6M |
| Q4 25 | $-14.3M | $10.2M | ||
| Q3 25 | $108.3M | $-1.1M | ||
| Q2 25 | $4.4M | $12.5M | ||
| Q1 25 | $-53.4M | $5.4M | ||
| Q4 24 | $19.3M | $35.6M | ||
| Q3 24 | — | $15.1M | ||
| Q2 24 | $-8.4M | $19.2M | ||
| Q1 24 | $-133.3M | $7.8M |
| Q4 25 | -7.1% | 7.6% | ||
| Q3 25 | 23.6% | -0.8% | ||
| Q2 25 | 2.5% | 9.5% | ||
| Q1 25 | -32.0% | 4.0% | ||
| Q4 24 | 9.1% | 29.4% | ||
| Q3 24 | — | 11.1% | ||
| Q2 24 | -4.2% | 11.7% | ||
| Q1 24 | -77.3% | 4.9% |
| Q4 25 | 0.1% | 2.4% | ||
| Q3 25 | 0.0% | 2.1% | ||
| Q2 25 | 0.0% | 1.8% | ||
| Q1 25 | 0.0% | 2.2% | ||
| Q4 24 | 0.0% | 1.9% | ||
| Q3 24 | 0.0% | 2.1% | ||
| Q2 24 | 0.0% | 2.5% | ||
| Q1 24 | 0.2% | 1.7% |
| Q4 25 | — | — | ||
| Q3 25 | 0.50× | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | 416.65× | ||
| Q4 24 | — | 2.38× | ||
| Q3 24 | — | 6.03× | ||
| Q2 24 | — | 6.15× | ||
| Q1 24 | — | 3.28× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
APLS
| Syfovre | $155.2M | 78% |
| Empaveli Pegcetacoplan | $35.1M | 18% |
| Licensing And Other Revenue | $9.6M | 5% |
MEC
| Fabrication | $72.2M | 54% |
| Construction And Access | $19.2M | 14% |
| Tubes | $16.2M | 12% |
| Other Market | $11.9M | 9% |
| Agriculture | $7.7M | 6% |
| Military | $6.7M | 5% |
| Outdoor Sports | $1.7M | 1% |
